Privacy and transparency are among the core points to consider when utilizing big data in rheumatic and musculoskeletal disorders (RMDs), according to the first EULAR-endorsed recommendations for use of big datasets in research.
A combination of tocilizumab and methotrexate reduced disease activity at 2 years compared with methotrexate plus prednisone in patients with early rheumatoid arthritis (RA), an effect not demonstrated with tocilizumab monotherapy.
The selective Janus kinase 1 inhibitor upadacitinib demonstrated sustained efficacy and safety beyond 12 weeks in patients with moderate-to-severe rheumatoid arthritis (RA) who had inadequate response or were refractory to disease-modifying antirheumatic drugs (DMARDs), according to the interim results of the ongoing extension phases of SELECT-NEXT* and SELECT-BEYOND** presented at EULAR 2019.
Both inflammatory bowel disease (IBD) and type 1 diabetes (T1D) are highly prevalent among patients who eventually develop rheumatoid arthritis (RA), indicating that these two conditions are potential risk factors for RA, according to a study presented at EULAR 2019.
Early use of the oral Janus kinase 1/2 inhibitor baricitinib led to enhanced clinical, functional, and radiographic efficacy compared with methotrexate monotherapy in patients with rheumatoid arthritis (RA), according to data presented at EULAR 2019.
The anti-interleukin (IL)-23p19 monoclonal antibody tildrakizumab showed better efficacy over placebo, along with a favourable safety profile, in patients with active psoriatic arthritis (PsA), according to a phase IIb study presented at EULAR 2019.
Glucocorticoid therapy can be safely tapered while maintaining high treatment success rates in patients with rheumatoid arthritis (RA) who had achieved disease control on tocilizumab, at the cost of a slight loss of disease control, suggests a randomized study presented at the EULAR 2019 Congress.